The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings

References

• Al-Farsi K. Multiple myeloma: an update. Oman Med J. 2013;28(1):3–11. doi:10.5001/omj.2013.02
   PubMedGoogle Scholar
• Noll JE, Williams SA, Purton LE, Zannettino ACW. Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J. 2012;2(9):e91. doi:10.1038/bcj.2012.38
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Cowan A, Allen C, Barac A, et al. Global burden of multiple myeloma - A systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227. doi:10.1001/jamaoncol.2018.2128
   PubMed Web of Science ®Google Scholar
• Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51(4):479–491. doi:10.1038/bmt.2015.307
   PubMed Web of Science ®Google Scholar
• Robinson D, Orlowski R, Stokes M, et al. Economic burden of relapsed or refractory multiple myeloma: results from an international trial. Eur J Hematol. 2017;99(2):119–132. doi:10.1111/ejh.12876
   PubMed Web of Science ®Google Scholar
• He J, Duenas A, Collacott H, et al. Patient perceptions regarding multiple myeloma and its treatment: qualitative evidence from interviews with patients in the United Kingdom, France, and Germany. Patient. 2021;14(5):613–623. doi:10.1007/s40271-021-00501-7
   PubMedGoogle Scholar
• Mian HS, Pond GR, Wildes TM, Sivapathasundaram B, Sussman J, Seow H. Symptom burden in transplant ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Haematologica. 2020;106(7):1991–1994. doi:10.3324/haematol.2020.267757
   Web of Science ®Google Scholar
• Quiñoa-Salanova C, Porta-Sales J, Monforte-Royo C, Edo-Gual M. The experiences and needs of primary family caregivers of patients with multiple myeloma: a qualitative analysis. Palliat Med. 2019;33(5):500–509. doi:10.1177/0269216319830017
   PubMed Web of Science ®Google Scholar
• Morris M, Marshall-Lucette S. The experience of myeloma caregivers during home-based oral chemotherapy treatment: a qualitative study. Semin Oncol Nurs. 2017;33(3):362–371. doi:10.1016/j.soncn.2017.05.010
   PubMed Web of Science ®Google Scholar
• Joo CW, Quach H, Raje N. Perspectives in the rapidly evolving treatment landscape of multiple myeloma: expert review of new data presentations from ASH 2019. Clin Lymphoma Myeloma Leuk. 2020;20(11):724–735. doi:10.1016/j.clml.2020.06.015
   PubMed Web of Science ®Google Scholar
• Mian HS, Fiala MA, Wildes TM. Burden of treatment among older adults with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;21(2):e152–9. doi:10.1016/j.clml.2020.09.010
   PubMed Web of Science ®Google Scholar
• Merola D, Yong C, Noga S, Shermock K. Costs associated with productivity loss among U.S. patients newly diagnosed with multiple myeloma receiving oral versus injectable chemotherapy. J Manag Care Spec Pharm. 2018;24(10):1019–1026. doi:10.18553/jmcp.2018.24.10.1019
   PubMed Web of Science ®Google Scholar
• Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–308. doi:10.1097/NCC.0b013e3182693522
   PubMed Web of Science ®Google Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–337. doi:10.3350/cmh.2014.20.4.327
   PubMedGoogle Scholar
• House of Commons Library. Informal Carers [Internet]. Briefing paper; 2021 [ cited April 8, 2021]. Available from: https://researchbriefings.files.parliament.uk/documents/CBP-7756/CBP-7756.pdf. Accessed November 9, 2022.
   Google Scholar
• Oken MM, Creech RH, Davis TE. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol Cancer Clin Trials. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi:10.2165/00019053-199304050-00006
   PubMed Web of Science ®Google Scholar
• Graf C. The Lawton instrumental activities of daily living scale. Am J Nurs. 2008;108(4):52–62. doi:10.1097/01.NAJ.0000314810.46029.74
   PubMed Web of Science ®Google Scholar
• Quality of Life - EORTC: EORTC [Internet]; [ cited March 18, 2021]. Available from: https://www.eortc.org/research_field/quality-of-life/. Accessed November 9, 2022.
   Google Scholar
• Proskorovsky I, Lewis P, Williams CD, et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12(1):35. doi:10.1186/1477-7525-12-35
   PubMed Web of Science ®Google Scholar
• Shelkey M, Wallace M. Katz index of independence in activities of daily living. J Gerontol Nurs. 1999;25(3):8–9. doi:10.3928/0098-9134-19990301-05
   PubMedGoogle Scholar
• Hoefman RJ, van Exel J, Brouwer WBF. Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. Health Qual Life Outcomes. 2013;11(1):173. doi:10.1186/1477-7525-11-173
   PubMed Web of Science ®Google Scholar
• Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–91. doi:10.1136/ard.2009.117150
   PubMed Web of Science ®Google Scholar
• Gol-Montserrat J, Del Burgo MLM, Quecedo L, Del Llano JE. Analysis of productivity costs in cancer: a systematic review. Glob Reg Heal Technol Assess Ital North Eur Spanish. 2017;4(1):5000262.
   Web of Science ®Google Scholar
• Cenzer I, Berger K, Rodriguez AM, Ostermann H, Covinsky KE. Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source. Aging Clin Exp Res. 2020;32(6):1153–1160. doi:10.1007/s40520-019-01465-3
   PubMed Web of Science ®Google Scholar
• Larsen RF, Jarden M, Minet LR, Frølund UC, Möller S, Abildgaard N. Physical function in patients newly diagnosed with multiple myeloma; A Danish cohort study. BMC Cancer. 2020;20(1):1–11. doi:10.1186/s12885-020-6637-6
   Web of Science ®Google Scholar
• Pearman T. Health and quality of life outcomes quality of life and psychosocial adjustment in gynecologic cancer survivors. Health Qual Life Outcomes. 2003;1(1):33. doi:10.1186/1477-7525-1-33
   PubMedGoogle Scholar
• Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018;24(8):1546–1553. doi:10.1016/j.bbmt.2018.03.027
   PubMed Web of Science ®Google Scholar
• Nielsen LK, Stege C, Lissenberg-Witte B, et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, Phase 3 study. Haematologica. 2020;105(6):1650–1659. doi:10.3324/haematol.2019.222299
   PubMed Web of Science ®Google Scholar
• Perrot A, Facon T, Plesner T, et al. Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the Phase III MAIA trial. J Clin Oncol. 2021;39(3):227–237. doi:10.1200/JCO.20.01370
   PubMed Web of Science ®Google Scholar
• Karacan Y, Akkus Y, Ozcelik ET, Ali R. Identification of psychological and social problems in caregivers of individuals diagnosed with hematologic malignancy. Asia-Pacific J Oncol Nurs. 2021;8(2):204–210. doi:10.4103/apjon.apjon_53_20
   PubMed Web of Science ®Google Scholar
• Myeloma UK. A life in Limbo 2016 A Myeloma UK research report on the experiences of myeloma carers in the UK [Internet]; 2016 [ cited July 26, 2021]. cited July 26, 2021: www.myeloma.org.uk. Accessed November 9, 2022.
   Google Scholar
• Pereira MG, Vilaça M, Pinheiro M, et al. Quality of life in caregivers of patients with multiple myeloma. Aging Ment Health. 2020;24(9):1402–1410. doi:10.1080/13607863.2019.1617240
   PubMed Web of Science ®Google Scholar
• Schulz R, Sherwood PR. Physical and mental health effects of family caregiving. Am J Nurs. 2008;108(9):23–27. doi:10.1097/01.NAJ.0000336406.45248.4c
   PubMed Web of Science ®Google Scholar
• La IS, Yun EK. Effects of stress appraisal on the quality of life of adult patients with multiple myeloma and their primary family caregivers in Korea. Psychooncology. 2017;26(10):1640–1646. doi:10.1002/pon.4348
   PubMed Web of Science ®Google Scholar
• Neves M, Trigo F,Rui B, et al. Multiple myeloma in Portugal: burden of disease and cost of illness. Pharmacoeconomics. 2021;39(5):579–587. doi:10.1007/s40273-020-00993-5
   PubMed Web of Science ®Google Scholar
• Antunes L, Rocha-Gonçalves F, Chacim S, et al. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. Eur J Cancer Care (Engl). 2019;28(4):e13026. doi:10.1111/ecc.13026
   PubMed Web of Science ®Google Scholar
• Robert B, Miroslava R. Direct and indirect costs associated with multiple myeloma: a case study from the Slovak Republic. Int Healthc J. 2017;1:11–16.
   Google Scholar
• Petrucci MT, Calabrese E, Levi A, et al. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori. 2013;99(4):e193–e202. doi:10.1177/030089161309900434
   PubMedGoogle Scholar
• Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015;2(10):e408–16. doi:10.1016/S2352-3026(15)00151-9
   PubMed Web of Science ®Google Scholar
• Mankinen P, Vihervaara V, Torvinen S, Martikainen J, Soini E. Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland. J Med Econ. 2019;22(4):328–335. doi:10.1080/13696998.2019.1569457
   PubMed Web of Science ®Google Scholar
• Anand Padala S, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(3). doi:10.3390/medsci9010003
   Google Scholar
• Jackson G, Galinsky J, Alderson DEC, et al. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy. Eur J Haematol. 2019;103(4):393–401.
   PubMed Web of Science ®Google Scholar
• Tachi T, Teramachi H, Tanaka K, et al. The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis. Springerplus. 2016;5(1):32.
   PubMedGoogle Scholar
• de Moor JS, Dowling EC, Ekwueme DU, et al. Employment implications of informal cancer caregiving. J Cancer Surviv. 2017;11(1):48–57. doi:10.1007/s11764-016-0560-5
   PubMed Web of Science ®Google Scholar